144 related articles for article (PubMed ID: 19944969)
1. The epidermal growth factor variant III peptide vaccine for treatment of malignant gliomas.
Li G; Mitra S; Wong AJ
Neurosurg Clin N Am; 2010 Jan; 21(1):87-93. PubMed ID: 19944969
[TBL] [Abstract][Full Text] [Related]
2. Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas.
Del Vecchio CA; Li G; Wong AJ
Expert Rev Vaccines; 2012 Feb; 11(2):133-44. PubMed ID: 22309662
[TBL] [Abstract][Full Text] [Related]
3. Prospect of rindopepimut in the treatment of glioblastoma.
Elsamadicy AA; Chongsathidkiet P; Desai R; Woroniecka K; Farber SH; Fecci PE; Sampson JH
Expert Opin Biol Ther; 2017 Apr; 17(4):507-513. PubMed ID: 28274144
[TBL] [Abstract][Full Text] [Related]
4. EGFRvIII-targeted vaccination therapy of malignant glioma.
Choi BD; Archer GE; Mitchell DA; Heimberger AB; McLendon RE; Bigner DD; Sampson JH
Brain Pathol; 2009 Oct; 19(4):713-23. PubMed ID: 19744042
[TBL] [Abstract][Full Text] [Related]
5. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.
Sampson JH; Archer GE; Mitchell DA; Heimberger AB; Bigner DD
Semin Immunol; 2008 Oct; 20(5):267-75. PubMed ID: 18539480
[TBL] [Abstract][Full Text] [Related]
6. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.
Heimberger AB; Sampson JH
Expert Opin Biol Ther; 2009 Aug; 9(8):1087-98. PubMed ID: 19591631
[TBL] [Abstract][Full Text] [Related]
7. Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.
Swartz AM; Li QJ; Sampson JH
Immunotherapy; 2014; 6(6):679-90. PubMed ID: 25186601
[TBL] [Abstract][Full Text] [Related]
8. Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme.
Del Vecchio CA; Wong AJ
Curr Opin Mol Ther; 2010 Dec; 12(6):741-54. PubMed ID: 21154166
[TBL] [Abstract][Full Text] [Related]
9. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.
Schuster J; Lai RK; Recht LD; Reardon DA; Paleologos NA; Groves MD; Mrugala MM; Jensen R; Baehring JM; Sloan A; Archer GE; Bigner DD; Cruickshank S; Green JA; Keler T; Davis TA; Heimberger AB; Sampson JH
Neuro Oncol; 2015 Jun; 17(6):854-61. PubMed ID: 25586468
[TBL] [Abstract][Full Text] [Related]
10. The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.
Paff M; Alexandru-Abrams D; Hsu FP; Bota DA
Hum Vaccin Immunother; 2014; 10(11):3322-31. PubMed ID: 25625931
[TBL] [Abstract][Full Text] [Related]
11. The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme.
Chistiakov DA; Chekhonin IV; Chekhonin VP
Eur J Pharmacol; 2017 Sep; 810():70-82. PubMed ID: 28583430
[TBL] [Abstract][Full Text] [Related]
12. Targeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma.
Sonabend AM; Dana K; Lesniak MS
Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S45-50. PubMed ID: 18076318
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for glioma: getting closer to the clinical arena?
Finocchiaro G; Pellegatta S
Curr Opin Neurol; 2011 Dec; 24(6):641-7. PubMed ID: 22027543
[TBL] [Abstract][Full Text] [Related]
14. A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.
Tsuboi A; Hashimoto N; Fujiki F; Morimoto S; Kagawa N; Nakajima H; Hosen N; Nishida S; Nakata J; Morita S; Sakamoto J; Oji Y; Oka Y; Sugiyama H
Cancer Immunol Immunother; 2019 Feb; 68(2):331-340. PubMed ID: 30430205
[TBL] [Abstract][Full Text] [Related]
15. EGF receptor variant III as a target antigen for tumor immunotherapy.
Li G; Wong AJ
Expert Rev Vaccines; 2008 Sep; 7(7):977-85. PubMed ID: 18767947
[TBL] [Abstract][Full Text] [Related]
16. Clinical applications of a peptide-based vaccine for glioblastoma.
Kanaly CW; Ding D; Heimberger AB; Sampson JH
Neurosurg Clin N Am; 2010 Jan; 21(1):95-109. PubMed ID: 19944970
[TBL] [Abstract][Full Text] [Related]
17. A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors.
Moscatello DK; Ramirez G; Wong AJ
Cancer Res; 1997 Apr; 57(8):1419-24. PubMed ID: 9108438
[TBL] [Abstract][Full Text] [Related]
18. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model.
Ciesielski MJ; Kazim AL; Barth RF; Fenstermaker RA
Cancer Immunol Immunother; 2005 Feb; 54(2):107-19. PubMed ID: 15340764
[TBL] [Abstract][Full Text] [Related]
19. Targeting EGFRvIII for glioblastoma multiforme.
Yang J; Yan J; Liu B
Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
[TBL] [Abstract][Full Text] [Related]
20. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.
Sampson JH; Archer GE; Mitchell DA; Heimberger AB; Herndon JE; Lally-Goss D; McGehee-Norman S; Paolino A; Reardon DA; Friedman AH; Friedman HS; Bigner DD
Mol Cancer Ther; 2009 Oct; 8(10):2773-9. PubMed ID: 19825799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
